Why is the universe ripping itself apart? A new study of exploding stars shows dark energy may be more complicated than we thought 
Doing science in Antarctica has harmed an environment under great pressure. Here's how we can do better 
The brightest object in the universe is a black hole that eats a star a day 
Six space missions to look forward to in 2024 
Customizing mRNA is easy, and that's what makes it the next frontier for personalized medicine − a molecular biologist explains 
The brain is the most complicated object in the universe. This is the story of scientists’ quest to decode it – and read people’s minds 
What is minoxidil, the anti-balding hair growth treatment? Here’s what the science says 
How do airplanes fly? An aerospace engineer explains the physics of flight 
If life exists on Jupiter’s moon Europa, scientists might soon be able to detect it 
Genetic diseases: How scientists are working to make DNA repair (almost) a piece of cake 
Our survey of the sky is uncovering the secrets of how planets are born 
The mystery of consciousness shows there may be a limit to what science alone can achieve 
There has yet to be a definitive cure for COVID-19, which has claimed hundreds of thousands of lives and the numbers only seem to rise for many countries. With Donald Trump contracting the coronavirus last week and claiming to have made a full recovery thanks to the cocktail of drugs given to him, the company responsible, Regeneron, is now requesting the FDA for an emergency use approval.
Biotech company Regeneron has filed a request to the Food & Drug Administration for an emergency use approval of the drug cocktail given to the US President as a potential COVID-19 cure. The drug in question called REGN-COV2 was pushed by Trump as a cure after it was administered to him last week upon contracting the virus. There has yet to be scientific proof that this type of therapy to treat coronavirus symptoms would be able to cure everyone of the disease.
Nevertheless, Regeneron has filed a request for the FDA to approve of its formulation. “If an EUA is granted the government has committed to making these doses available to the American people at no cost and would be responsible for their distribution,” said the company in a statement Wednesday.
Regeneron has also revealed that the treatment is available for 50,000 patients so far. Over the next few months, the company is expected to have produced enough for 300,000 patients. The drug cocktail is made up of to monoclonal antibodies and formulated to target the infectivity of the virus that causes COVID-19. Trump was given eight grams of this antibody even as the FDA has yet to give a green light for its use.
Meanwhile, medical authorities are also now tasked not only to look into a cure for COVID-19 but also to tackle a possible scarlet fever outbreak. According to scientists in Australia, there is a chance that the bacteria that causes scarlet fever has since undergone mutation, becoming stronger after it clashed with another virus.
In the United Kingdom alone between 2014 and 2018, there was a 68 percent rise in cases of scarlet fever, which usually affects children between five to 15 years old.
